Charles Albright, Ph.D.
Chief Scientific Officer
Charlie was most recently chief scientific officer at Editas Medicine where his research group advanced the pioneering CRISPR gene-editing platform and medicines from program inception to Investigational New Drug (IND) application. He has led research activities at both biotech and big pharma companies across a range of therapeutic areas, including neurology, neuromuscular, cardiovascular, ophthalmology, and oncology. Prior to Editas, he was vice president of genetically-defined diseases and genomics at Bristol Myers Squibb Company, where he was responsible for developing the group’s strategy and building a pipeline of novel therapeutics with a focus on central nervous system (CNS) and cardiovascular rare diseases. Before joining the industry, Charlie held academic positions at Vanderbilt University and Whitehead Institute for Biomedical Research. Charlie received a Bachelor of Science in chemical engineering and a doctorate in biology from Massachusetts Institute of Technology.